‡ These authors contributed equally Dedicated to Professor Dieter Enders Abstract A cationic ruthenium(II)-complex enabled unprecedented C–H methylations on indoles and pyrroles. The versatile catalyst proved to be widely applicable and delivered the methylated heteroarenes with excellent levels of positional selectivity and ample substrate scope. The robustness of the catalysts was reflected by the
[EN] 5-HT3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR 5-HT3
申请人:ENVOY THERAPEUTICS INC
公开号:WO2014014951A1
公开(公告)日:2014-01-23
The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Selectivity control in hydroarylation‐based C−H alkylation has been dominated by steric interactions. A conceptually distinct strategy that exploits the programmed switch in the C−H activation mechanism by means of cobalt catalysis is presented, which sets the stage for convenient C−H alkylations with unactivated alkenes. Detailed mechanistic studies provide compelling evidence for a programmable switch
A highly selective Mn(I)-catalyzed alkenylation of arenes and heteroarenes with 1,3-diynes is described. The reported transformation overcomes regio-, chemo-, and stereoselectivity challenges associated with the use of these coupling partners. Both symmetrical and unsymmetrical diynes can be applied in this protocol, affording single isomers not only in the synthesis of 1,3-enynes but also in the one-step